- Home
- IDAI vs CURX Comparison
IDAI vs CURX Comparison
Compare IDAI & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDAI | CURX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 14.5M |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | IDAI | CURX |
|---|---|---|
| Price | $2.64 | $0.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 37.8K | ★ 207.9K |
| Earning Date | 05-14-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $103.06 | N/A |
| Revenue Next Year | $140.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $0.26 |
| 52 Week High | $5.28 | $9.18 |
Technical Indicators
Market Signals| Indicator | IDAI | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 51.37 |
| Support Level | $2.31 | $0.38 |
| Resistance Level | $2.82 | $0.53 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 80.36 | 32.62 |
Price Performance
Historical ComparisonAbout IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.